Santaris Pharma has received approval for an investigational new drug application (IND) for the agent SPC2996 in the treatment of chronic lymphocytic leukemia (CLL).
SPC2996 is an RNA antagonist that has been designed to reduce Bcl-2 protein levels within tumor cells, by binding to Bcl-2 messenger RNA.
A phase I/II study is currently ongoing to evaluate SPC2996 in relapsed or refractory CLL.
© 1998-2007 OncoEd.com All Rights Reserved.
These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.